American journal of respiratory and critical care medicine

publication venue for

Severe Cavitary, Fistulating Mycobacterium avium-intracellulare Complex Disease in an Immunocompetent Host. 2015
An official American Thoracic Society/European Respiratory Society statement: Update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. 2013
Bilateral pulmonary sequestration. 2011
Acute eosinophilic pneumonia in a New York City firefighter exposed to World Trade Center dust. 2002
Recurrence of desquamative interstitial pneumonia after lung transplantation. 1997
Reply to Moor et al. and Egashira et al. 2025
Associations of High Attenuation Area-related Proteomic Biomarkers with Fibrotic or Subpleural Interstitial Lung Abnormalities. 2025
Breaking Barriers: Enhancing Access, Equity, and Efficiency in ILD Clinical Trials. 2025
Proteomic Biomarkers of Survival in Non-Idiopathic Pulmonary Fibrosis Interstitial Lung Disease.. 211. 2025
From Crisis to Control: The Novel Use of a Vascular Plug for Refractory Airway Hemorrhage. 2025
Deep Learning Estimation of Small Airway Disease from Inspiratory Chest Computed Tomography: Clinical Validation, Repeatability, and Associations with Adverse Clinical Outcomes in Chronic Obstructive Pulmonary Disease.. 211. 2025
Metabolomic Evidence of Biological Overlap with HFpEF in a Subset of Pulmonary Arterial Hypertension. 2025
Post-COPD: Can Emphysema Be Repaired? 2025
Impact of the CAPTURE Chronic Obstructive Pulmonary Disease Screening Tool in U.S. Primary Care: A Cluster-Randomized Trial.. 211. 2025
Associations of Pre-Pandemic Lung Function and Structure with COVID-19 Outcomes: The C4R Study. 2025
Temporal Exploration of Chronic Obstructive Pulmonary Disease Phenotypes: Insights from the COPDGene and SPIROMICS Cohorts.. 211. 2025
Climate Change & COPD: A GOLD Science Committee Review. 2025
Assessment of Home-based Monitoring in Adults with Chronic Lung Disease: An Official American Thoracic Society Research Statement.. 211. 2025
Effect of Triple Therapy on Cardiovascular and Severe Cardiopulmonary Events in Chronic Obstructive Pulmonary Disease: A Post Hoc Analysis of a Randomized, Double-Blind, Phase 3 Clinical Trial (ETHOS).. 211. 2025
Efficacy and Safety of Admilparant, an LPA₁ Antagonist, in Pulmonary Fibrosis: A Phase 2 Randomized Clinical Trial.. 211. 2025
Serum Immunoglobulin G Levels Are Associated with Risk for Exacerbations: An Analysis of SPIROMICS.. 211. 2025
Association of Ground-Glass Opacities with Systemic Inflammation and Progression of Emphysema.. 210. 2024
Association Between Baseline Driving Pressure and Mortality in Very Old Patients with Acute Respiratory Distress Syndrome.. 210. 2024
Call to Action: How Can We Promote the Development of New Pharmacologic Treatments in Chronic Obstructive Pulmonary Disease?. 210. 2024
Preacinar Arterial Dilation Mediates Outcomes of Quantitative Interstitial Abnormalities in the COPDGene Study.. 210. 2024
Biological Age, Chronological Age, and Survival in Pulmonary Fibrosis: A Causal Mediation Analysis.. 210. 2024
Evaluation of Etomidate Use and Association with Mortality Compared with Ketamine Among Critically Ill Patients. 2024
Machine Learning of Plasma Proteomics Classifies Diagnosis of Interstitial Lung Disease.. 210. 2024
Molecular Endotypes of Idiopathic Pulmonary Fibrosis: A Latent Class Analysis of Two Multicenter Observational Cohorts.. 210. 2024
The Role of Inflammation and Fibrosis in Interstitial Lung Disease Treatment Decisions.. 210. 2024
Dysanapsis Genetic Risk Predicts Lung Function Across the Lifespan. 2024
Serum Cell-Free DNA-based Detection of Mycobacterium avium Complex Infection.. 209. 2024
Commensal Oral Microbiota, Disease Severity, and Mortality in Fibrotic Lung Disease.. 209. 2024
Proteomic Biomarkers of Quantitative Interstitial Abnormalities in COPDGene and CARDIA Lung Study.. 209. 2024
Proteomic Biomarkers of Survival in Idiopathic Pulmonary Fibrosis.. 209. 2024
Zinpentraxin Alfa for Idiopathic Pulmonary Fibrosis: The Randomized Phase III STARSCAPE Trial.. 209. 2024
The Effect of Chronic Altitude Exposure on COPD Outcomes in the SPIROMICS Cohort. 2024
Meaningful Endpoints for Idiopathic Pulmonary Fibrosis (IPF) Clinical Trials: Emphasis on 'Feels, Functions, Survives'. Report of a Collaborative Discussion in a Symposium with Direct Engagement from Representatives of Patients, Investigators, the National Institutes of Health, a Patient Advocacy Organization, and a Regulatory Agency.. 209. 2024
Early Diagnosis and Treatment of COPD: The Costs and Benefits of Case-Finding. 2024
Pulmonary Fibrosis Stakeholder Summit: A Joint NHLBI, Three Lakes Foundation, and Pulmonary Fibrosis Foundation Workshop Report.. 209. 2024
Loss of Airway Phylogenetic Diversity Is Associated with Clinical and Pathobiological Markers of Disease Development in COPD. 2024
Temporal Trends in Mortality of Critically Ill Patients with Sepsis in the United Kingdom, 1988-2019. 2024
Clonal Somatic Mutations in Chronic Lung Diseases Are Associated with Reduced Lung Function.. 208. 2023
Indoor Pollution and Lung Function Decline in Current and Former Smokers: SPIROMICS AIR.. 208. 2023
Investigating Associations of Omega-3 Fatty Acids, Lung Function Decline, and Airway Obstruction.. 208. 2023
Treatment of Systemic Sclerosis-associated Interstitial Lung Disease: Evidence-based Recommendations. An Official American Thoracic Society Clinical Practice Guideline. 2023
Accounting for Competing Events when Evaluating Long-Term Outcomes in Survivors of Critical Illness. 2023
Repeatability of Pulmonary Quantitative Computed Tomography Measurements in Chronic Obstructive Pulmonary Disease.. 208. 2023
Lower Airway Dysbiosis Augments Lung Inflammatory Injury in Mild-to-Moderate COPD. 2023
Causes of and Clinical Features Associated with Death in Tobacco Cigarette Users by Lung Function Impairment.. 208. 2023
Icenticaftor, a CFTR Potentiator, in COPD: A Multicenter, Parallel-Group, Double-Blind Clinical Trial.. 208. 2023
Respiratory Health and Cities.. 208. 2023
Serial Sampling of the Small Airway Epithelium to Identify Persistent Smoking-dysregulated Genes. 2023
A Polygenic Risk Score for Idiopathic Pulmonary Fibrosis and Interstitial Lung Abnormalities. 2023
Validity and Reliability of the Fatigue Severity Scale in a Real-World Interstitial Lung Disease Cohort.. 208. 2023
PCSK6 and Survival in Idiopathic Pulmonary Fibrosis.. 207. 2023
A Unique Cellular Organization of Human Distal Airways and Its Disarray in Chronic Obstructive Pulmonary Disease.. 207. 2023
Global Initiative for Chronic Obstructive Lung Disease 2023 Report: GOLD Executive Summary.. 207. 2023
Do Thresholds for Invasive Ventilation in Hypoxemic Respiratory Failure Exist? A Cohort Study.. 207. 2023
Definition and Nomenclature of Chronic Obstructive Pulmonary Disease: Time for Its Revision.. 206. 2022
Prevalence and Mechanisms of Mucus Accumulation in COVID-19 Lung Disease.. 206. 2022
Pharmacotherapy and Mortality in Chronic Obstructive Pulmonary Disease.. 206. 2022
A Phase IIb Randomized Clinical Study of an Anti-α_vβ₆ Monoclonal Antibody in Idiopathic Pulmonary Fibrosis.. 206. 2022
Vasculopathy and Increased Vascular Congestion in Fatal COVID-19 and Acute Respiratory Distress Syndrome.. 206. 2022
Reversible Airflow Obstruction Predicts Future Chronic Obstructive Pulmonary Disease Development in the SPIROMICS Cohort: An Observational Cohort Study.. 206. 2022
Lung Microbiota and Metabolites Collectively Associate with Clinical Outcomes in Milder Stage Chronic Obstructive Pulmonary Disease.. 206. 2022
Syndrome of Combined Pulmonary Fibrosis and Emphysema: An Official ATS/ERS/JRS/ALAT Research Statement.. 206. 2022
Integrating Clinical Probability into the Diagnostic Approach to Idiopathic Pulmonary Fibrosis: An International Working Group Perspective.. 206. 2022
Rare and Common Variants in KIF15 Contribute to Genetic Risk of Idiopathic Pulmonary Fibrosis.. 206. 2022
Clinical Trial of Losartan for Pulmonary Emphysema: Pulmonary Trials Cooperative LEEP Trial. 2022
Liberation from Invasive Mechanical Ventilation with Continued Receipt of Vasopressor Infusions.. 205. 2022
Phase 2B Study of Inhaled RVT-1601 for Chronic Cough in Idiopathic Pulmonary Fibrosis: A Multicenter, Randomized, Placebo-controlled Study (SCENIC Trial).. 205. 2022
Associations of Monocyte Count and Other Immune Cell Types with Interstitial Lung Abnormalities.. 205. 2022
Long-Term Safety and Efficacy of Tocilizumab in Early Systemic Sclerosis-Interstitial Lung Disease: Open-Label Extension of a Phase 3 Randomized Controlled Trial.. 205. 2022
Race/Ethnicity, Spirometry Reference Equations, and Prediction of Incident Clinical Events: The Multi-Ethnic Study of Atherosclerosis (MESA) Lung Study.. 205. 2022
Alpha-1 Antitrypsin MZ Heterozygosity Is an Endotype of Chronic Obstructive Pulmonary Disease.. 205. 2022
Latent Class Analysis Reveals COVID-19-related Acute Respiratory Distress Syndrome Subgroups with Differential Responses to Corticosteroids.. 204. 2021
Racial Segregation and Respiratory Outcomes among Urban Black Residents with and at Risk of Chronic Obstructive Pulmonary Disease.. 204. 2021
Blood Transcriptomics Predicts Progression of Pulmonary Fibrosis and Associated Natural Killer Cells.. 204. 2021
Patient-centered Outcomes Research in Interstitial Lung Disease: An Official American Thoracic Society Research Statement.. 204. 2021
Attention to Immortal Time Bias in Critical Care Research.. 203. 2021
Contribution of Individual and Neighborhood Factors to Racial Disparities in Respiratory Outcomes.. 203. 2021
Mucus Plugs and Emphysema in the Pathophysiology of Airflow Obstruction and Hypoxemia in Smokers.. 203. 2021
Pharmacotherapy and Lung Function Decline in Patients with Chronic Obstructive Pulmonary Disease. A Systematic Review.. 203. 2021
Reduced All-Cause Mortality in the ETHOS Trial of Budesonide/Glycopyrrolate/Formoterol for Chronic Obstructive Pulmonary Disease. A Randomized, Double-Blind, Multicenter, Parallel-Group Study.. 203. 2021
Differential Responses to Targeting Matrix Metalloproteinase 9 in Idiopathic Pulmonary Fibrosis.. 203. 2021
Utility of a Molecular Classifier as a Complement to High-Resolution Computed Tomography to Identify Usual Interstitial Pneumonia.. 203. 2021
Informing Healthcare Decisions with Observational Research Assessing Causal Effect. An Official American Thoracic Society Research Statement.. 203. 2021
Use of Hydrocortisone, Ascorbic Acid, and Thiamine in Adults with Septic Shock.. 202. 2020
The Effect of Inhaled Corticosteroid Withdrawal and Baseline Inhaled Treatment on Exacerbations in the IMPACT Study. A Randomized, Double-Blind, Multicenter Clinical Trial.. 202. 2020
New Opioid Use after Invasive Mechanical Ventilation and Hospital Discharge.. 202. 2020
Expression of the SARS-CoV-2 ACE2 Receptor in the Human Airway Epithelium.. 202. 2020
Association of Premorbid Blood Pressure with Vasopressor Infusion Duration in Patients with Shock.. 202. 2020
Reduction in All-Cause Mortality with Fluticasone Furoate/Umeclidinium/Vilanterol in Patients with Chronic Obstructive Pulmonary Disease.. 201. 2020
Early Use of Adjunctive Therapies for Pediatric Acute Respiratory Distress Syndrome: A PARDIE Study.. 201. 2020
Hospital Preparedness for COVID-19: A Practical Guide from a Critical Care Perspective.. 201. 2020
A Human Lung Challenge Model to Evaluate the Safety and Immunogenicity of PPD and Live Bacillus Calmette-Guérin.. 201. 2020
Pharmacologic Management of Chronic Obstructive Pulmonary Disease. An Official American Thoracic Society Clinical Practice Guideline.. 201. 2020
The Effects of Rare SERPINA1 Variants on Lung Function and Emphysema in SPIROMICS.. 201. 2020
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.. 201. 2020
Nintedanib and Sildenafil in Patients with Idiopathic Pulmonary Fibrosis and Right Heart Dysfunction. A Prespecified Subgroup Analysis of a Double-Blind Randomized Clinical Trial (INSTAGE).. 200. 2019
Overlap of Genetic Risk between Interstitial Lung Abnormalities and Idiopathic Pulmonary Fibrosis.. 200. 2019
Diagnostic Likelihood Thresholds That Define a Working Diagnosis of Idiopathic Pulmonary Fibrosis.. 200. 2019
A Genetic Risk Score Associated with Chronic Obstructive Pulmonary Disease Susceptibility and Lung Structure on Computed Tomography.. 200. 2019
Noninvasive Imaging Biomarker Identifies Small Airway Damage in Severe Chronic Obstructive Pulmonary Disease.. 200. 2019
Update in Lung Infections and Tuberculosis 2018.. 200. 2019
Telomere Length and Use of Immunosuppressive Medications in Idiopathic Pulmonary Fibrosis.. 200. 2019
Design of Idiopathic Pulmonary Fibrosis Clinical Trials in the Era of Approved Therapies.. 200. 2019
Resequencing Study Confirms That Host Defense and Cell Senescence Gene Variants Contribute to the Risk of Idiopathic Pulmonary Fibrosis.. 200. 2019
Underdetection and Undertreatment of Dyspnea in Critically Ill Patients.. 199. 2019
Closing the Evidence Gap in Interstitial Lung Disease. The Promise of Real-World Data.. 199. 2019
Lung Microbiota Contribute to Pulmonary Inflammation and Disease Progression in Pulmonary Fibrosis.. 199. 2019
Omega-3 Fatty Acids and Genome-Wide Interaction Analyses Reveal DPP10-Pulmonary Function Association.. 199. 2019
Albuminuria, Lung Function Decline, and Risk of Incident Chronic Obstructive Pulmonary Disease. The NHLBI Pooled Cohorts Study.. 199. 2019
Ambient Pollution-related Reprogramming of the Human Small Airway Epithelial Transcriptome.. 198. 2018
Ontogeny and Biology of Human Small Airway Epithelial Club Cells.. 198. 2018
Determinants of Response to Roflumilast in Severe Chronic Obstructive Pulmonary Disease. Pooled Analysis of Two Randomized Trials.. 198. 2018
Patient-reported Outcomes for the Detection, Quantification, and Evaluation of Chronic Obstructive Pulmonary Disease Exacerbations.. 198. 2018
Exacerbations of Chronic Obstructive Pulmonary Disease and Cardiac Events. A Post Hoc Cohort Analysis from the SUMMIT Randomized Clinical Trial.. 198. 2018
At the Root: Defining and Halting Progression of Early Chronic Obstructive Pulmonary Disease.. 197. 2018
Update in Chronic Obstructive Pulmonary Disease 2017.. 197. 2018
Obstructive Sleep Apnea Severity Affects Amyloid Burden in Cognitively Normal Elderly. A Longitudinal Study.. 197. 2018
Preponderance of High-Grade Histologic Subtype in Autologous Metastases in Lung Adenocarcinoma.. 197. 2018
Fluticasone Furoate, Vilanterol, and Lung Function Decline in Patients with Moderate Chronic Obstructive Pulmonary Disease and Heightened Cardiovascular Risk.. 197. 2018
High-Attenuation Areas on Chest Computed Tomography and Clinical Respiratory Outcomes in Community-Dwelling Adults.. 196. 2017
A Standardized Diagnostic Ontology for Fibrotic Interstitial Lung Disease. An International Working Group Perspective.. 196. 2017
Serum Matrix Metalloproteinase-7, Respiratory Symptoms, and Mortality in Community-Dwelling Adults. MESA (Multi-Ethnic Study of Atherosclerosis).. 196. 2017
The "Iron"-y of Iron Overload and Iron Deficiency in Chronic Obstructive Pulmonary Disease.. 196. 2017
Occupational Exposures and Subclinical Interstitial Lung Disease. The MESA (Multi-Ethnic Study of Atherosclerosis) Air and Lung Studies.. 196. 2017
The Voice of Surrogate Decision-Makers. Family Responses to Prognostic Information in Chronic Critical Illness.. 196. 2017
NLRP3 Inflammasome Deficiency Protects against Microbial Sepsis via Increased Lipoxin B₄ Synthesis.. 196. 2017
A Comparative Analysis of Pulmonary and Critical Care Medicine Guideline Development Methodologies.. 196. 2017
Smoking-Dependent Distal-to-Proximal Repatterning of the Adult Human Small Airway Epithelium.. 196. 2017
Microbes Are Associated with Host Innate Immune Response in Idiopathic Pulmonary Fibrosis.. 196. 2017
A Pilot Study Linking Endothelial Injury in Lungs and Kidneys in Chronic Obstructive Pulmonary Disease.. 195. 2017
Outcomes after Rehospitalization at the Same Hospital or a Different Hospital Following Critical Illness.. 195. 2017
AJRCCM: 100-Year Anniversary. Progress in Interstitial Lung Disease.. 195. 2017
Effect of Fluticasone Furoate and Vilanterol on Exacerbations of Chronic Obstructive Pulmonary Disease in Patients with Moderate Airflow Obstruction.. 195. 2017
Idiopathic Pulmonary Fibrosis: The Association between the Adaptive Multiple Features Method and Fibrosis Outcomes.. 195. 2017
A New Approach for Identifying Patients with Undiagnosed Chronic Obstructive Pulmonary Disease.. 195. 2017
Age and Small Airway Imaging Abnormalities in Subjects with and without Airflow Obstruction in SPIROMICS.. 195. 2017
Biomarkers Predictive of Exacerbations in the SPIROMICS and COPDGene Cohorts.. 195. 2017
Chronic Respiratory Symptoms with Normal Spirometry. A Reliable Clinical Entity?. 195. 2017
Plasma Surfactant Protein-D, Matrix Metalloproteinase-7, and Osteopontin Index Distinguishes Idiopathic Pulmonary Fibrosis from Other Idiopathic Interstitial Pneumonias.. 194. 2016
Integrated Genomics Reveals Convergent Transcriptomic Networks Underlying Chronic Obstructive Pulmonary Disease and Idiopathic Pulmonary Fibrosis.. 194. 2016
SPIROMICS Protocol for Multicenter Quantitative Computed Tomography to Phenotype the Lungs.. 194. 2016
Current Controversies in the Pharmacological Treatment of Chronic Obstructive Pulmonary Disease.. 194. 2016
Effect of Roflumilast and Inhaled Corticosteroid/Long-Acting β2-Agonist on Chronic Obstructive Pulmonary Disease Exacerbations (RE(2)SPOND). A Randomized Clinical Trial.. 194. 2016
Pulmonary Abnormalities in Young, Light-Use Waterpipe (Hookah) Smokers.. 194. 2016
Gut Microbiota Predict Pulmonary Infiltrates after Allogeneic Hematopoietic Cell Transplantation.. 194. 2016
Association between Functional Small Airway Disease and FEV1 Decline in Chronic Obstructive Pulmonary Disease.. 194. 2016
Quantitative IFN-γ and IL-2 Response Associated with Latent Tuberculosis Test Discordance in HIV-infected Pregnant Women.. 193. 2016
IFN-γ-Producing T-Helper 17.1 Cells Are Increased in Sarcoidosis and Are More Prevalent than T-Helper Type 1 Cells.. 193. 2016
An American Thoracic Society Official Research Statement: Future Directions in Lung Fibrosis Research.. 193. 2016
Rhinovirus Detection in Symptomatic and Asymptomatic Children: Value of Host Transcriptome Analysis.. 193. 2016
Rising Billing for Intermediate Intensive Care among Hospitalized Medicare Beneficiaries between 1996 and 2010.. 193. 2016
TOLLIP, MUC5B, and the Response to N-Acetylcysteine among Individuals with Idiopathic Pulmonary Fibrosis.. 192. 2015
Pulmonary Microvascular Blood Flow in Mild Chronic Obstructive Pulmonary Disease and Emphysema. The MESA COPD Study.. 192. 2015
Detection of Rheumatoid Arthritis-Interstitial Lung Disease Is Enhanced by Serum Biomarkers.. 191. 2015
Indications and Effects of Plasma Transfusions in Critically Ill Children.. 191. 2015
Chronic Infection by Mucoid Pseudomonas aeruginosa Associated with Dysregulation in T-Cell Immunity to Outer Membrane Porin F.. 191. 2015
The impact of the organization of high-dependency care on acute hospital mortality and patient flow for critically ill patients.. 191. 2015
Airway basal cells. The "smoking gun" of chronic obstructive pulmonary disease.. 190. 2014
Predictors of chronic obstructive pulmonary disease exacerbation reduction in response to daily azithromycin therapy.. 189. 2014
Estimates of the need for palliative care consultation across united states intensive care units using a trigger-based model.. 189. 2014
Future directions in idiopathic pulmonary fibrosis research. An NHLBI workshop report.. 189. 2014
Loss of salmeterol bronchoprotection against exercise in relation to ADRB2 Arg16Gly polymorphism and exhaled nitric oxide.. 188. 2013
Syndecan-2 exerts antifibrotic effects by promoting caveolin-1-mediated transforming growth factor-β receptor I internalization and inhibiting transforming growth factor-β1 signaling.. 188. 2013
Acellular normal and fibrotic human lung matrices as a culture system for in vitro investigation.. 186. 2012
A placebo-controlled randomized trial of warfarin in idiopathic pulmonary fibrosis.. 186. 2012
Statins and pulmonary fibrosis: the potential role of NLRP3 inflammasome activation.. 185. 2012
Poloxamer 188 facilitates the repair of alveolus resident cells in ventilator-injured lungs.. 184. 2011
BUILD-3: a randomized, controlled trial of bosentan in idiopathic pulmonary fibrosis.. 184. 2011
Comparison of medical admissions to intensive care units in the United States and United Kingdom.. 183. 2011
Circulating endothelial microparticles as a measure of early lung destruction in cigarette smokers.. 184. 2011
Mesenchymal stromal cells in bronchoalveolar lavage as predictors of bronchiolitis obliterans syndrome.. 183. 2010
HIV infection and risk for incident pulmonary diseases in the combination antiretroviral therapy era.. 183. 2010
Threshold of biologic responses of the small airway epithelium to low levels of tobacco smoke.. 182. 2010
Prognostic importance of hyponatremia in patients with acute pulmonary embolism.. 182. 2010
Chronic obstructive pulmonary disease phenotypes: the future of COPD.. 182. 2010
Increased cytokine response of rhinovirus-infected airway epithelial cells in chronic obstructive pulmonary disease.. 182. 2010
Noninfectious pneumonitis after everolimus therapy for advanced renal cell carcinoma.. 182. 2010
Clinical predictors of a diagnosis of idiopathic pulmonary fibrosis.. 181. 2010
Physiological and computed tomographic predictors of outcome from lung volume reduction surgery.. 181. 2009
Pulmonary hypertension and computed tomography measurement of small pulmonary vessels in severe emphysema.. 181. 2009
Lung dendritic cell expression of maturation molecules increases with worsening chronic obstructive pulmonary disease.. 180. 2009
Use of intensive care services during terminal hospitalizations in England and the United States.. 180. 2009
Superior immune response to protein-conjugate versus free pneumococcal polysaccharide vaccine in chronic obstructive pulmonary disease.. 180. 2009
Integrating health status and survival data: the palliative effect of lung volume reduction surgery.. 180. 2009
Genetic risk factors for portopulmonary hypertension in patients with advanced liver disease.. 179. 2009
Interleukin-17-mediated immunopathogenesis in experimental hypersensitivity pneumonitis.. 179. 2009
Down-regulation of the notch pathway in human airway epithelium in association with smoking and chronic obstructive pulmonary disease.. 179. 2008
The prognostic value of cardiopulmonary exercise testing in idiopathic pulmonary fibrosis.. 179. 2008
Longitudinal change in the BODE index predicts mortality in severe emphysema.. 178. 2008
An essential role for fibronectin extra type III domain A in pulmonary fibrosis.. 177. 2007
Potential value of regionalized intensive care for mechanically ventilated medical patients.. 177. 2007
Inhibition of integrin alpha(v)beta6, an activator of latent transforming growth factor-beta, prevents radiation-induced lung fibrosis.. 177. 2007
Variable prostaglandin E2 resistance in fibroblasts from patients with usual interstitial pneumonia.. 177. 2007
Diffuse lung disease in young children: application of a novel classification scheme.. 176. 2007
Impaired flow-mediated dilation is associated with low pulmonary function and emphysema in ex-smokers: the Emphysema and Cancer Action Project (EMCAP) Study.. 176. 2007
Early interstitial lung disease in familial pulmonary fibrosis.. 176. 2007
Survival after lung volume reduction in chronic obstructive pulmonary disease: insights from small airway pathology.. 176. 2007
Sex differences in severe pulmonary emphysema.. 176. 2007
Genetic determinants of emphysema distribution in the national emphysema treatment trial.. 176. 2007
Course of FEV(1) after onset of bronchiolitis obliterans syndrome in lung transplant recipients.. 175. 2007
Intermittent hypoxia causes insulin resistance in lean mice independent of autonomic activity.. 175. 2007
Idiopathic interstitial pneumonia: do community and academic physicians agree on diagnosis?. 175. 2007
Idiopathic pulmonary fibrosis: prognostic value of changes in physiology and six-minute-walk test.. 174. 2006
Predictors of mortality in patients with emphysema and severe airflow obstruction.. 173. 2006
Genetic association analysis of functional impairment in chronic obstructive pulmonary disease.. 173. 2006
Negative regulation of myofibroblast differentiation by PTEN (Phosphatase and Tensin Homolog Deleted on chromosome 10).. 173. 2005
Prognostic value of bronchiolitis obliterans syndrome stage 0-p in single-lung transplant recipients.. 172. 2005
Tuberculosis, nontuberculous lung infection, pleural disorders, pulmonary function, respiratory muscles, occupational lung disease, pulmonary infections, and social issues in AJRCCM in 2004.. 171. 2005
The association of acetaminophen, aspirin, and ibuprofen with respiratory disease and lung function.. 171. 2005
Physiology is a stronger predictor of survival than pathology in fibrotic interstitial pneumonia.. 171. 2005
Idiopathic interstitial pneumonia: what is the effect of a multidisciplinary approach to diagnosis?. 170. 2004
Enhanced monocyte chemoattractant protein-3/CC chemokine ligand-7 in usual interstitial pneumonia.. 170. 2004
Relationship of serum antioxidants to asthma prevalence in youth.. 169. 2003
Sitaxsentan therapy for pulmonary arterial hypertension.. 169. 2003
Maximal oxygen uptake and severity of disease in lymphangioleiomyomatosis.. 168. 2003
A randomized controlled trial of adaptive ventilation for Cheyne-Stokes breathing in heart failure.. 168. 2003
Prognostic value of desaturation during a 6-minute walk test in idiopathic interstitial pneumonia.. 168. 2003
Prognostic implications of physiologic and radiographic changes in idiopathic interstitial pneumonia.. 168. 2003
Fibroblastic foci in usual interstitial pneumonia: idiopathic versus collagen vascular disease.. 167. 2003
Bleomycin-induced pulmonary fibrosis is attenuated in gamma-glutamyl transpeptidase-deficient mice.. 167. 2002
Future research directions in idiopathic pulmonary fibrosis: summary of a National Heart, Lung, and Blood Institute working group.. 166. 2002
Histopathologic variability in usual and nonspecific interstitial pneumonias.. 164. 2001
Reversible airflow obstruction, proliferation of abnormal smooth muscle cells, and impairment of gas exchange as predictors of outcome in lymphangioleiomyomatosis.. 164. 2001
Unexplained exertional limitation: characterization of patients with a mitochondrial myopathy.. 164. 2001
Preserved spontaneous breathing improves cardiac output during partial liquid ventilation.. 164. 2001
Maintenance of cAMP in non-heart-beating donor lungs reduces ischemia-reperfusion injury.. 163. 2001
Human collagenase (matrix metalloproteinase-1) expression in the lungs of patients with emphysema.. 163. 2001
Classification of sleep-disordered breathing.. 163. 2001
Differential patterns of apoptosis in resolving and nonresolving bacterial pneumonia.. 161. 2000
Increase of lung neutrophils in hypersensitivity pneumonitis is associated with lung fibrosis.. 161. 2000
Downregulation of estrogen and progesterone receptors in the abnormal smooth muscle cells in pulmonary lymphangioleiomyomatosis following therapy. An immunohistochemical study.. 161. 2000
Feasibility of a clinical trial of augmentation therapy for alpha(1)-antitrypsin deficiency. The Alpha 1-Antitrypsin Deficiency Registry Study Group.. 161. 2000
Fine mapping of PPH1, a gene for familial primary pulmonary hypertension, to a 3-cM region on chromosome 2q33.. 161. 2000
The utility of open lung biopsy in patients with hematologic malignancies.. 161. 2000
Respiratory response during arm elevation in isolated diaphragm weakness.. 160. 1999
Outcomes after long-term acute care. An analysis of 133 mechanically ventilated patients.. 159. 1999
Analysis of risk factors for the development of bronchiolitis obliterans syndrome.. 159. 1999
Acidosis stimulates nitric oxide production and lung damage in rats.. 159. 1999
Outcomes and resource utilization for patients with prolonged critical illness managed by university-based or community-based subspecialists.. 158. 1998
Severe community-acquired pneumonia. Assessment of severity criteria.. 158. 1998
Acute respiratory distress syndrome caused by pulmonary and extrapulmonary disease. Different syndromes?. 158. 1998
Survival and FEV1 decline in individuals with severe deficiency of alpha1-antitrypsin. The Alpha-1-Antitrypsin Deficiency Registry Study Group.. 158. 1998
A "closed" medical intensive care unit (MICU) improves resource utilization when compared with an "open" MICU.. 157. 1998
Do molecular markers predict survival in non-small-cell lung cancer?. 157. 1998
Idiopathic pulmonary fibrosis: predicting response to therapy and survival.. 157. 1998
Impact of invasive and noninvasive quantitative culture sampling on outcome of ventilator-associated pneumonia: a pilot study.. 157. 1998
Risk of tuberculin conversion according to occupation among health care workers at a New York City hospital.. 156. 1997
Lung-volume reduction improves dyspnea, dynamic hyperinflation, and respiratory muscle function.. 155. 1997
Lack of clinical utility of bronchoalveolar lavage cultures for cytomegalovirus in HIV infection.. 155. 1997
Neutrophil rheologic changes in septic shock.. 155. 1997
Activated neutrophils secrete stored alpha 1-antitrypsin.. 154. 1996
Clinical features of individuals with PI*SZ phenotype of alpha 1-antitrypsin deficiency. alpha 1-Antitrypsin Deficiency Registry Study Group.. 154. 1996
Increased expression of gelatinases and collagenase in rat lungs exposed to 100% oxygen.. 154. 1996
Lung mechanics and dyspnea after lung transplantation for chronic airflow obstruction.. 153. 1996
Endobronchial ultrasound-guided needle aspiration of mediastinal adenopathy.. 153. 1996
Quantitative assessment of the epithelial and inflammatory cell populations in large airways of normals and individuals with cystic fibrosis.. 153. 1996
Relationship between procedures and health insurance for critically ill patients with Pneumocystis carinii pneumonia.. 152. 1995
Guidelines for the initial management of community-acquired pneumonia: savory recipe or cookbook for disaster?. 152. 1995
Supplemental oxygen during sleep in children with sleep-disordered breathing.. 152. 1995
Cytokines affect pseudomonas binding to tracheal cells via a neutrophil-mediated process.. 152. 1995
Transmission of multidrug-resistant tuberculosis in a large urban setting.. 152. 1995
Increased interleukin-1 receptor antagonist in idiopathic pulmonary fibrosis. A compartmental analysis.. 151. 1995
Radiologic evaluation of emphysema in patients with chronic obstructive pulmonary disease. Chest radiography versus high resolution computed tomography.. 151. 1995
Chemotherapeutic activity of clofazimine and its analogues against Mycobacterium tuberculosis. In vitro, intracellular, and in vivo studies.. 151. 1995
A rapid preadmission method for predicting inpatient course of disease for patients with HIV-related Pneumocystis carinii pneumonia.. 150. 1994
Limitations of spirometry in detecting rejection after single-lung transplantation.. 150. 1994
Protease-antiprotease imbalance in the lungs of children with cystic fibrosis.. 150. 1994
Pulmonary function abnormalities in thalassemia major and the role of iron overload.. 149. 1994
Prediction of Health-related Quality of Life and Hospitalization in Pulmonary Arterial Hypertension: The Pulmonary Hypertension Association Registry.. 203. 2021
Evaluation of the 2016 Infectious Diseases Society of America/American Thoracic Society Guideline Criteria for Risk of Multidrug-Resistant Pathogens in Patients with Hospital-acquired and Ventilator-associated Pneumonia in the ICU.. 197. 2018
Distinct Serum Sphingolipid Profiles among School-aged Children with Exercise-induced Wheeze and Asthma Persistence.. 195. 2017
Cigarette Smoking Induces Changes in Airway Epithelial Expression of Genes Associated with Monogenic Lung Disorders.. 193. 2016
Insomnia.. 190. 2014
Reply: Characterization of lymphangioleiomyomatosis as a neoplastic disease.. 188. 2013
Shock and pulmonary edema secondary to severe acute hypercapnic acidosis.. 184. 2011
Are physicians' recommendations on limiting life support really burdensome?. 181. 2010
Surgical lung biopsy in the diagnosis of idiopathic NSIP: do we always need it in the initial approach?. 179. 2009
Importance of Mcl-1 for Alveolar Macrophage Apoptosis-associated Bacterial Killing. 2019
Basal-like Cells in the BAL Fluid: An Echo of Regenerative Crisis in Idiopathic Pulmonary Fibrosis Lungs. 2019
Reply to Londhe et al.: CAPTURE: A Screening Tool for Chronic Obstructive Pulmonary Disease or Obstructive Airway Disease? 2018
Patient-centered Outcomes in Idiopathic Pulmonary Fibrosis Clinical Trials. 2017
Reply: Epithelial-Mesenchymal Transition: A Necessary New Therapeutic Target in Chronic Obstructive Pulmonary Disease? 2017
Novel Discoveries and Advances in Management of Acute Respiratory Distress Syndrome. 2017
Reply: Not So New. 2017
Reply: The New Idiopathic Pulmonary Fibrosis Acute Exacerbations Document: One Step Ahead but Still Suspended in the Air. 2017
Long-Term Outcomes after Critical Illness. The Best Predictor of the Future Is the Past. 2016
Reply to Hua et al.: The Driving Pressure Setting of Acute Respiratory Distress Syndrome: Beyond the Age. 2025
Exercise Limitation in Pulmonary Hypertension - Physiological Insights into the 6-Minute Walk Test. 2024
Reply to Stowasser et al.: Assessing How Patients Feel, Function, and Survive in Idiopathic Pulmonary Fibrosis: The Best Is the Enemy of the Good. 2024
Early Mortality in Clinical Trials of Acute Respiratory Distress Syndrome. 2024
Reply to Gan et al. 2023
Genome-wide Enrichment of TERT Rare Variants in Idiopathic Pulmonary Fibrosis Patients of Latino Ancestry. 2022
Reply by Elmaleh-Sachs et al. to Townsend and Cowl, and to Miller et al. 2022
Obstructive Sleep Apnea and Hypertension with Longitudinal Amyloid-β Burden and Cognitive Changes. 2022
Toll-Interacting Protein and Altered Lung Microbiota in Idiopathic Pulmonary Fibrosis. 2022
Reply to López-Campos et al. and to Rogliani and Calzetta. 2021
Reply to López-Campos et al.: Triple-Therapy Trials for Chronic Obstructive Pulmonary Disease: Methodological Considerations in the Mortality Effect. 2021
Effect of Neutropenic Critical Illness on Development and Prognosis of Acute Respiratory Distress Syndrome. 2021
Reply to Wang and Lai: The Role of Eosinophils during the Withdrawal of Inhaled Corticosteroids in Chronic Obstructive Pulmonary Disease. 2021
Reply to Sharma and Zeki: Does Vaping Increase Susceptibility to COVID-19? 2020
Pulse Wave Velocity in Chronic Obstructive Pulmonary Disease and the Impact of Inhaled Therapy (SUMMIT): A Randomized Double-Blind Clinical Trial. 2020
Reply to Janssen and Wouters: Loss of Alveolar Attachments as a Pathomechanistic Link between Small Airway Disease and Emphysema. 2020
Alveolar Macrophage Immunometabolism and Lung Function Impairment in Smoking and Chronic Obstructive Pulmonary Disease. 2020
Radiographic Honeycombing and Altered Lung Microbiota in Patients with Idiopathic Pulmonary Fibrosis. 2019
Which Biopsy to Diagnose Interstitial Lung Disease? A Call for Evidence and Unity. 2019
Association between Emphysema and Chronic Obstructive Pulmonary Disease Outcomes in the COPDGene and SPIROMICS Cohorts: A Post Hoc Analysis of Two Clinical Trials. 2018
Long-Acting β-Agonist/Inhaled Corticosteroid in Patients with Chronic Obstructive Pulmonary Disease with Cardiovascular Disease or Risk: A Factorial Analysis of the SUMMIT Clinical Trial. 2018
Reply to Fernández Pérez: Diagnostic Decision-Making in Hypersensitivity Pneumonitis: Toward a Consensus Statement. 2018
Intraalveolar Catecholamines and the Human Lung Microbiome. 2015
Intensivist workforce in the United States: the crisis is real, not imagined. 2015
Airway Basal stem/progenitor cells have diminished capacity to regenerate airway epithelium in chronic obstructive pulmonary disease. 2014
Reply: Palliative care: a core competency for intensive care unit doctors. 2014
Changes in physician reimbursement by medicare for critical care services from 1998 to 2008. 2013
Reply: idiopathic pulmonary fibrosis: perspectives on clinically meaningful primary endpoints in phase 3 clinical trials. 2013
Lung transplantation: opportunities for research and clinical advancement. 2006
Watching an Evolution in Progress, Cutting-Edge Research Transforming Outcomes in Interstitial Lung Disease: Introduction to an AJRCCM Special Section.. 211. 2025
Airtime for the Airway.. 211. 2025
Big Things Have Small Beginnings: Clinical Implications of Early Interstitial Lung Disease.. 210. 2024
Pioneering Research Driving Progress toward a Cure for Interstitial Lung Disease (ILD): Introduction to the AJRCCM Special Issue on ILD (Part 2).. 210. 2024
Monotherapy or Combination Therapy for Septic Shock? A Debate on Steroids.. 209. 2024
Watching an Evolution in Progress, Cutting-Edge Research Transforming Outcomes in Interstitial Lung Disease: Introduction to an AJRCCM Special Issue.. 209. 2024
Are Airway Epithelial p73 Levels a Therapeutic Target to Treat Chronic Obstructive Pulmonary Disease?. 209. 2024
Phoenix from the Ashes: Celebrating the 2023 North American Cystic Fibrosis Conference.. 208. 2023
CEACAM6: A Novel Marker of Chronic Obstructive Pulmonary Disease Susceptibility?. 207. 2023
AJRCCM: Strength in Breadth.. 207. 2023
"KEAP"ing Alveolar Macrophage Mitochondria Content in Chronic Obstructive Pulmonary Disease.. 207. 2023
Introducing "Viewpoint: Turning the Air Blue".. 207. 2023
What COVID-19 Has Taught Us: Ventilator-associated Pneumonia Is Back!. 206. 2022
Inequity and the Interstitium: Pushing Back on Disparities in Fibrosing Lung Disease in the United States and Canada.. 205. 2022
Advancing Global Respiratory Health, Sleep, and Critical Care: Editorial from the New American Journal of Respiratory and Critical Care Medicine Team.. 205. 2022
Ending on a Crescendo: Reflections on Seven Years of a Successful Journal.. 204. 2021
The Saga of Necroptosis in Chronic Obstructive Pulmonary Disease Continues.. 204. 2021
Pinpointing the Cause of Variation in Mortality in COVID-19.. 204. 2021
The Challenges of Defining Early Chronic Obstructive Pulmonary Disease in the General Population.. 203. 2021
More Evidence for Inborn Dysregulation of Sphingolipid Metabolism in Children with Asthma?. 203. 2021
Antibiotic Use in Sepsis: How and Why Less Can Really Mean More (Survival).. 203. 2021
COVID-19 and Interstitial Lung Disease: Keep Them Separate.. 202. 2020
One More Time: The Impact of Inhaled Corticosteroid Withdrawal on IMPACT.. 202. 2020
The Origins of Chronic Obstructive Pulmonary Disease: Sometimes the Journey Matters More than the Destination.. 202. 2020
Mechanical Ventilation in COVID-19: Interpreting the Current Epidemiology.. 202. 2020
Life at the Editorial "COVID Frontline". The American Thoracic Society Journal Family.. 201. 2020
When Intensive Care Becomes Good End-of-Life Care.. 201. 2020
Can Macrolide Antibiotics Prevent Hospital Readmissions?. 200. 2019
ILD: Upcoming Themed Issue.. 199. 2019
Computed Tomographic Biomarkers in Idiopathic Pulmonary Fibrosis. The Future of Quantitative Analysis.. 199. 2019
Determination of Early Immune Function in Sepsis and Its Influence on Organ Dysfunction. Is a More Pragmatic Outcome on the Horizon?. 198. 2018
Manmade Macrophage Offers a New Therapy for Pulmonary Alveolar Proteinosis.. 198. 2018
Intensifying Long-Acting β-Agonist/Corticosteroid Therapy at Acute Exacerbations of Chronic Obstructive Pulmonary Disease.. 197. 2018
Airway Epithelial Progenitors and the Natural History of Chronic Obstructive Pulmonary Disease.. 197. 2018
Seeing Deeply into the Lung in Interstitial Lung Disease.. 197. 2018
Circulating Mitochondrial DNA as a Mechanism-based, Prognostic Biomarker for Idiopathic Pulmonary Fibrosis.. 196. 2017
Midkine: In the Middle of the Pathogenesis of Acute Respiratory Distress Syndrome-associated Lung Fibrosis?. 192. 2015
Macrolide-Resistant Pneumococcus in Community-acquired Pneumonia. Is There Still a Role for Macrolide Therapy?. 191. 2015
Insights into intensive care unit bed expansion in the United States. National and regional analyses.. 191. 2015
Untangling the healthcare use patterns of severe sepsis survivors.. 190. 2014
Are the smoking-induced diseases an acquired form of cystic fibrosis?. 188. 2013
The lung microbiome and viral-induced exacerbations of chronic obstructive pulmonary disease: new observations, novel approaches.. 188. 2013
The microbiota in respiratory disease.. 185. 2012
Baseline values and short serial change: a "road map" for a poor early outcome in idiopathic pulmonary fibrosis.. 184. 2011
The IPFnet Strategy: Creating a comprehensive approach in the treatment of idiopathic pulmonary fibrosis.. 181. 2010
Gender and chronic obstructive pulmonary disease: why it matters.. 176. 2007
Does the presence of antibodies justify the use of antibiotics in exacerbations of chronic bronchitis?. 169. 2004
Inducible nitric oxide synthase in the tuberculous human lung.. 166. 2002
On the contagious nature of tuberculosis (continued).. 165. 2002
Is "crop rotation" of antibiotics the solution to a "resistant" problem in the ICU?. 156. 1997
The non-small cell lung cancer immune contexture. A major determinant of tumor characteristics and patient outcome. 2015
Update in respiratory infections 2011. 2012
Chronic critical illness. 2010
NHLBI Workshop Summary. Report of workshop on lymphangioleiomyomatosis. National Heart, Lung, and Blood Institute. 1999
Genetics and Genomics of Pulmonary Fibrosis: Charting the Molecular Landscape and Shaping Precision Medicine. 2024
Phenotypes, Etiotypes, and Endotypes of Exacerbations of Chronic Obstructive Pulmonary Disease. 2023
Prevalence, Risk Factors, and Outcomes of Adult Interstitial Lung Abnormalities: A Systematic Review and Meta-Analysis. 2023
An Update on Outcomes for COPD Pharmacological Trials: A COPD Investigators Report - Reassessment of the 2008 American Thoracic Society/European Respiratory Society Statement on Outcomes for COPD Pharmacological Trials. 2023
Targeting Type 2 Inflammation and Epithelial Alarmins in Chronic Obstructive Pulmonary Disease: A Biologics Outlook. 2023
Blood Eosinophils and Chronic Obstructive Pulmonary Disease: A Global Initiative for Chronic Obstructive Lung Disease Science Committee 2022 Review. 2022
International Differences in the Frequency of Chronic Obstructive Pulmonary Disease Exacerbations Reported in Three Clinical Trials. 2022
Cystic Fibrosis Transmembrane Conductance Regulator: Roles in Chronic Obstructive Pulmonary Disease. 2022
Treatment Trials in Young Patients with Chronic Obstructive Pulmonary Disease and Pre-Chronic Obstructive Pulmonary Disease Patients: Time to Move Forward. 2022
Update in Interstitial Lung Disease 2020. 2021
Update in Critical Care 2020. 2021
Global Initiative for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease. The 2020 GOLD Science Committee Report on COVID-19 and Chronic Obstructive Pulmonary Disease. 2021
Blood Eosinophil Counts in Clinical Trials for Chronic Obstructive Pulmonary Disease. 2020
Update in Interstitial Lung Disease 2019. 2020
Why Does an Aging Smoker's Lung Develop Idiopathic Pulmonary Fibrosis and Not Chronic Obstructive Pulmonary Disease? 2019
The Low-Risk Profile in Pulmonary Arterial Hypertension. Time for a Paradigm Shift to Goal-oriented Clinical Trial Endpoints? 2018
The Role of Danger Signals in the Pathogenesis and Perpetuation of Critical Illness. 2018
The Role of Chest Computed Tomography in the Evaluation and Management of the Patient with Chronic Obstructive Pulmonary Disease. 2017
Diagnosis and Treatment of Fibrotic Hypersensitivity Pneumonia. Where We Stand and Where We Need to Go. 2017
Update in Critical Care 2016. 2017
An Official American Thoracic Society Systematic Review: The Effect of Nighttime Intensivist Staffing on Mortality and Length of Stay among Intensive Care Unit Patients. 2017
Acute Exacerbation of Idiopathic Pulmonary Fibrosis. An International Working Group Report. 2016
Precision Medicine: The New Frontier in Idiopathic Pulmonary Fibrosis. 2016
Update in Interstitial Lung Disease 2014. 2015
The role of stepdown beds in hospital care. 2014
IFN-γ release assays in the diagnosis of latent tuberculosis infection among immunocompromised adults. 2013
Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. 2012
Genome-wide association studies identify CHRNA5/3 and HTR4 in the development of airflow obstruction. 2012
The National Emphysema Treatment Trial (NETT) Part II: Lessons learned about lung volume reduction surgery. 2011
The National Emphysema Treatment Trial (NETT): Part I: Lessons learned about emphysema. 2011
Acute exacerbations of idiopathic pulmonary fibrosis. 2007
Update in diffuse parenchymal lung diseases 2005. 2006
Interstitial lung disease, lung cancer, lung transplantation, pulmonary vascular disorders, and sleep-disordered breathing in AJRCCM in 2004. 2005
Advances in critical care hepatology. 2003
Pulmonary cell biology. 1998
Gene therapy for the respiratory manifestations of cystic fibrosis. 1995
Idiopathic Pulmonary Fibrosis (an Update) and Progressive Pulmonary Fibrosis in Adults: An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline. 2022
Diagnosis of Idiopathic Pulmonary Fibrosis. An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline. 2018
An Official American Thoracic Society/European Society of Intensive Care Medicine/Society of Critical Care Medicine Clinical Practice Guideline: Mechanical Ventilation in Adult Patients with Acute Respiratory Distress Syndrome. 2017
Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 2017 Report. GOLD Executive Summary. 2017
An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline: Treatment of Idiopathic Pulmonary Fibrosis. An Update of the 2011 Clinical Practice Guideline. 2015
An official American Thoracic Society/American Association of Critical-Care Nurses/American College of Chest Physicians/Society of Critical Care Medicine policy statement: the Choosing Wisely® Top 5 list in Critical Care Medicine. 2014
An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. 2011
Standards and indications for cardiopulmonary sleep studies in children. American Thoracic Society. 1996

VIVO Weill Cornell Medical College

American journal of respiratory and critical care medicine Journal

Overview

publication venue for

Identity

ISO Abbreviation

Linking ISSN

International Standard Serial Number (ISSN)

Electronic International Standard Serial Number (EISSN)